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Abstract 
A total of 1,561 pigs (initially 4 d of age) were used to determine the effects of a porcine reproductive and 
respiratory syndrome virus (PRRSv) subunit vaccine, PRRSV-RS (Sirrah-Bios, Ames, IA), on mortality rate 
and finisher pig growth performance in a PRRSv-positive commercial herd. Pigs were randomly assigned 
by litter to either the subunit PRRSv vaccine or non-vaccinated control group. Pigs in the vaccinated group 
received an intramuscular injection of 1 mL PRRSV-RS vaccine at processing (approximately 4 d after 
birth) and again at weaning (approximately 24 d of age). Vaccinated and control pigs were comingled in a 
single nursery during the nursery phase. In the finishing phase, pigs were housed in a standard 
commercial curtain-sided finisher barn by treatment and gender by pen, with treatments randomly 
distributed across pens. Mortality was tracked from processing (4 d of age) to market (d 187 to 193). 
There was no difference between the control and vaccinated pigs for cumulative mortality (21.5% vs. 
20.6%, P = 0.67) or for mortality during each production phase (processing to weaning: 9.5% vs. 7.1%, P = 
0.08; nursery: 9.3% vs. 9.2%, P = 0.95; finishing: 4.4% vs. 5.9%, P = 0.20). Pigs were initially weighed by 
single-sex pens (control or vaccinated) 2 wk after placement into the finisher (d 0), and at that time, 
control and vaccinated mean pig weights were not different (58.4 vs. 58.7 lb, P = 0.90). Pens of pigs were 
subsequently weighed every 2 wk, and feed consumption was recorded to calculate ADG, ADFI, and F/G. 
Overall (d 0 to 112), control and vaccinated pig performance was similar (ADG: 1.96 vs. 1.93 lb, P = 0.45; 
ADFI: 5.35 vs. 5.36 lb, P = 0.94; F/G: 2.74 vs. 2.78, P = 0.15) throughout the finishing period. This resulted 
in no difference (P = 0.79) in off-test (d 112) weights between control (271.9 lb) and vaccinated (270.4 lb) 
pigs. These data indicate that this subunit PRRSv vaccine did not affect finisher pig performance or 
mortality in this commercial herd.; Swine Day, Manhattan, KS, November 19, 2009 
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Table 1. Effect of PRRSV-RS vaccine on growth performance of finisher pigs1
Treatment2
Item Control Vaccinated Probability, P <
Initial	wt,	lb 58.4	±	1.7 58.7	±	1.7 0.90
d	0	to	112
					ADG,	lb 1.96	±	0.03 1.93	±	0.03 0.45
					ADFI,	lb 5.35	±	0.08 5.36	±	0.08 0.94
					F/G 2.74	±	0.02 2.78	±	0.02 0.15












Table 2. Effect of PRRSV-RS vaccine on within-period and cumulative mortality1
Treatment2
Probability,	P <Item Control Vaccinate
Inventory
					Processing3 781 780 ---
					Weaning4 707 725 ---
					Entry	to	finisher5 641 658 ---
					Off	test6,7 529 535 ---
Within-period	mortality
					Processing	to	weaning,	% 9.5 7.1 0.08
					Nursery,	% 9.3 9.2 0.95
					Finisher,	% 4.4 5.9 0.20
Cumulative	mortality
					Processing	to	weaning,	% 9.5 7.1 0.08
					Processing	to	end	of	nursery,	% 17.9 15.6 0.23
					Processing	to	off	test,	%6 21.5 20.6 0.67
1	A	total	of	1,561	pigs	(barrows	or	gilts)	from	140	litters	across	5	sow	farms	were	assigned	to	1	of	2	treatments	
at	processing	(4	d	of	age)	by	randomly	assigning	entire	litters	to	either	the	vaccinated	or	non-vaccinated	control	
groups.	Control	and	vaccinated	pigs	were	comingled	in	the	nursery	and	then	separated	by	vaccine	treatment	and	
gender	in	the	finisher	barn.	Mortality	was	tracked	for	controls	and	vaccinates	from	processing	to	the	end	of	the	
finishing	portion	of	the	trial.
2	Treatments	were:	Control	=	no	vaccine	administered	and	Vaccinated	=	1	mL	PRRSV-RS	administered	intra-
muscularly	at	processing	and	weaning.	
3	4	d	of	age.	
4	Weaning	age	range	was	20	to	26	d	of	age.
5	Entry-to-finisher	age	range	was	60	to	66	d	of	age.
6	Off-test	age	range	was	187	to	193	d	of	age.
7	Inventory	at	off	test	(d	112)	excludes	pigs	marketed	(84	controls	and	84	vaccinates)	on	d	90	of	the	trial.
